Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLIC-1901 for Relapsed/Refractory CD19+ Hematologic Malignancies
NCT03765177Phase 2Recruiting
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Oct 2019
- Primary completion
- Jan 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CLIC-1901 in acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), sponsored by Ottawa Hospital Research Institute. Primary endpoints: Proportion of participants experiencing either Grade 3 or 4 cytokine release syndrome at 28 days, Overall Response Rate at 6 months and 1 more. Started Oct 2019; status: recruiting.
02
Drugs
CLIC-1901
03
Conditions
acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03765177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03765177.